Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia
- 211 Downloads
- 27 Citations
Abstract
Introduction
The aim of this trial was to gather data on the long-term safety of a new erythropoietin preparation (epoetin zeta), focusing on the formation of anti-erythropoietin antibodies, when administered intravenously for maintenance of target hemoglobin concentration in anemic patients with end-stage renal failure receiving chronic hemodialysis. In addition, we aimed to provide information on the efficacy of epoetin zeta under open, noncontrolled conditions.
Methods
Patients received epoetin zeta intravenously, 1–3 times/week for 56 weeks (overall patient group, n=745) or 108 weeks (Bulgarian subgroup, n=164). The aim of treatment was to maintain hemoglobin values between 10.5 and 12.5 g/dL with constant epoetin dosage. Primary (safety) endpoints were the occurrence of anti-erythropoietin antibodies and the evaluation of adverse events (AEs). Secondary (efficacy) endpoints included the mean weekly dose of epoetin per kg of body weight and mean hemoglobin concentrations.
Results
No patients developed neutralizing anti-erythropoietin antibodies. The most commonly reported AEs were infections and infestations (34.1%); followed by injury, poisoning, and procedural complications (25.8%); and gastrointestinal disorders (21.9%); 37.3% of patients reported serious AEs. The hemoglobin values remained stable, with mean values after 56 weeks of 11.3–11.6 g/dL for the overall group and 11.1–11.6 g/dL for the Bulgarian subgroup. The dosage of epoetin zeta was stable throughout the course of the trial. No cases of lack of (or loss of ) efficacy were observed in the course of the trial.
Conclusions
The evaluation of the primary endpoints provided data supporting the intravenous administration of epoetin zeta in patients with chronic renal failure. Neutralizing antibodies against erythropoietin were not detected, and there were no reports of patients with increasing erythropoietin resistance. Our results suggest that intravenous administration of epoetin zeta is effective regarding its ability to maintain stabilized hemoglobin levels within the target range of 10.5–12.5 g/dL.
Keywords
efficacy epoetin zeta erythropoietin long-term safety maintenance treatment renal anemiaPreview
Unable to display preview. Download preview PDF.
References
- 1.Ridley DM, Dawkins F, Perlin E. Erythropoietin: a review. J Natl Med Assoc. 1994;86:129–135.PubMedGoogle Scholar
- 2.Wang GL, Semenza GL. Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol. 1996;3:156–162.PubMedCrossRefGoogle Scholar
- 3.Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant. 1999;14:22–28.PubMedCrossRefGoogle Scholar
- 4.Erypo/Erypo Product information. Neuss, Germany: JANSSEN-CILAG GmbH Germany; 2002.Google Scholar
- 5.Levin A. Identification of patients and risk factors in chronic kidney disease-evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant. 2001;16:57–60.PubMedCrossRefGoogle Scholar
- 6.Tarif N. Anemia management in patients with chronic renal disease: current recommendations. Saudi J Kidney Dis Transpl. 2002;13:331–335.PubMedGoogle Scholar
- 7.Macdougall IC. Treatment of renal anemia with recombinant human erythropoietin. Curr Opin Nephrol Hypertens. 1992;1:210–219.PubMedCrossRefGoogle Scholar
- 8.Gregory N. Quality of life in patients on dialysis: benefits of maintaining a hemoglobin of 11 to 12 g/dL. Nephrol Nurs J. 2005;32:307–310.PubMedGoogle Scholar
- 9.Popovsky MA, Ransil BJ. Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. Immunohematol. 1996;12:1–3.Google Scholar
- 10.Tsakiris D. Morbidity and mortality reduction associated with the use of erythropoietin. Nephron. 2000;85 (suppl. 1):2–8.PubMedCrossRefGoogle Scholar
- 11.Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10:1309–1316.PubMedGoogle Scholar
- 12.European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products. CHMP/437/04. London: EMEA; October 2005. Available at: www.emea.europa.eu/pdfs/human/biosimilar/043704en.pdf. Accessed September 2, 2008.Google Scholar
- 13.European Medicines Agency. Committee for Medicinal Products for Human Use. Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-clinical and Clinical Issues: Guidance on Similar Medicinal Products Containing Recombinant Erythropoietins. EMEA/CHMP/BMWP/94526/2005 Corr. London: EMEA; March 2006. Available at: www.emea.europa.eu/pdfs/human/biosimilar/9452605en.pdf. Accessed September 2, 2008.Google Scholar
- 14.Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. The epoetin zeta study group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24: 625–637.PubMedCrossRefGoogle Scholar
- 15.Krivoshiev S, Todorov V, Manitius J, Czekalski S, Scigalla P, Koytchev R. Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anemia. Curr Med Res Opin. 2008;24:1407–1415.PubMedCrossRefGoogle Scholar
- 16.World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. World Medical Association web site. Available at: www.wma.net/e/policy/b3.htm. Accessed September 2, 2008.
- 18.ICH Topic E 6. Guideline for Good Clinical Practice. Step 5, Consolidated Guideline from 01.05.1996. Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). Woden, Australia: TGA; 2000. Available at: www.tga.gov.au/docs/pdf/euguide/ich/ich13595.pdf. Accessed September 2, 2008.Google Scholar
- 19.Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl. 2):1–47.Google Scholar
- 20.European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. CHMP/14327/06. London: EMEA; December 2007. Available at: www.emea.europa.eu/pdfs/human/biosimilar/1432706enfin.pdf. Accessed September 2, 2008.Google Scholar
- 21.Tacey R, Greyway A, Smiell J, et al. The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J Immunol Meth. 2003;283:317–329.CrossRefGoogle Scholar
- 22.Casadevall N. Epoetin-induced autoimmune pure red cell aplasia. Hematol J. 2004;5(suppl. 3):104–109.CrossRefGoogle Scholar
- 23.Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004;73:389–396.PubMedCrossRefGoogle Scholar
- 24.Adamson JW, Eschbach JW. Erythropoietin for end-stage renal disease. N Engl J Med. 1998;339;625–627.PubMedCrossRefGoogle Scholar
- 25.Eprex Product information. Toronto, ON: Janssen-Ortho CA Inc.; 2006.Google Scholar
- 26.NeoRecormon Product information. Welwyn Garden City, Hertfordshire: Roche Registration Ltd.; 2002.Google Scholar
- 27.Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003,64:1514–1521.PubMedCrossRefGoogle Scholar
- 28.Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992–1000.PubMedGoogle Scholar
- 29.Samtleben W, Ehmer B, Lutz-Knochenhauer I, Hagmann C, Scigalla P, Gurland HJ. Side effects during recombinant human erythropoietin therapy in 2000 ESRD patients. Contrib Nephrol. 1991;88:107–116.PubMedGoogle Scholar